Treatment modalities for Māori and New Zealand European men with localised prostate cancer

Verfasser / Beitragende:
[Zuzana Obertová, Ross Lawrenson, Nina Scott, Michael Holmes, Charis Brown, Chunhuan Lao, Leanne Tyrie, Peter Gilling]
Ort, Verlag, Jahr:
2015
Enthalten in:
International Journal of Clinical Oncology, 20/4(2015-08-01), 814-820
Format:
Artikel (online)
ID: 605491313
LEADER caa a22 4500
001 605491313
003 CHVBK
005 20210128100509.0
007 cr unu---uuuuu
008 210128e20150801xx s 000 0 eng
024 7 0 |a 10.1007/s10147-014-0781-4  |2 doi 
035 |a (NATIONALLICENCE)springer-10.1007/s10147-014-0781-4 
245 0 0 |a Treatment modalities for Māori and New Zealand European men with localised prostate cancer  |h [Elektronische Daten]  |c [Zuzana Obertová, Ross Lawrenson, Nina Scott, Michael Holmes, Charis Brown, Chunhuan Lao, Leanne Tyrie, Peter Gilling] 
520 3 |a Abstract : Objectives: To examine diagnostic and treatment pathways for Māori (the indigenous people of New Zealand [NZ]) and NZ European men with prostate cancer in order to identify causes of higher mortality rates for Māori men. Methods: All Māori men (150) diagnosed with prostate cancer in the Midland Cancer Network region between 2007 and 2010 were identified from the NZ Cancer Registry and frequency age-matched with three randomly sampled NZ European men. Clinical records of these men were searched for information on clinical stage at diagnosis, comorbidities, and type of treatment for localised disease. Results: The final cohort included 136 Māori and 400 NZ European men, of whom 97 Māori and 311 NZ European were diagnosed with localised prostate cancer. Māori men were twice as likely to be diagnosed with distant metastases compared with NZ European men (19.1 vs 9.8%). Māori men with localised disease were less likely to be treated with radical prostatectomy compared with NZ European men [RR 0.66 (95% CI 0.48, 0.90)]. Multivariate regression analysis adjusted for age, D'Amico risk strata, comorbidities, and socioeconomic deprivation showed that Māori men were more likely to be managed expectantly [RR 1.74 (95% CI 1.06, 2.57)]. Conclusion: Differences between Māori and NZ European men observed in the management of localised prostate cancer cannot be readily explained by patient characteristics, such as comorbidities or risk assessment at diagnosis. Poorer outcomes for Māori men may not only be related to later stage at diagnosis but differences in treatment modalities may also be a factor. 
540 |a Japan Society of Clinical Oncology, 2015 
690 7 |a Active surveillance  |2 nationallicence 
690 7 |a Ethnicity  |2 nationallicence 
690 7 |a Radical prostatectomy  |2 nationallicence 
690 7 |a Radiotherapy  |2 nationallicence 
690 7 |a Watchful waiting  |2 nationallicence 
700 1 |a Obertová  |D Zuzana  |u Waikato Clinical School, Peter Rothwell Academic Centre, University of Auckland, Private Bag 3200, 3240, Hamilton, New Zealand  |4 aut 
700 1 |a Lawrenson  |D Ross  |u Waikato Clinical School, Peter Rothwell Academic Centre, University of Auckland, Private Bag 3200, 3240, Hamilton, New Zealand  |4 aut 
700 1 |a Scott  |D Nina  |u Te Puna Oranga, Waikato District Health Board, Hamilton, New Zealand  |4 aut 
700 1 |a Holmes  |D Michael  |u Urology Department, Waikato Hospital, Hamilton, New Zealand  |4 aut 
700 1 |a Brown  |D Charis  |u Waikato Clinical School, Peter Rothwell Academic Centre, University of Auckland, Private Bag 3200, 3240, Hamilton, New Zealand  |4 aut 
700 1 |a Lao  |D Chunhuan  |u Waikato Clinical School, Peter Rothwell Academic Centre, University of Auckland, Private Bag 3200, 3240, Hamilton, New Zealand  |4 aut 
700 1 |a Tyrie  |D Leanne  |u Radiation Oncology, Waikato Hospital, Hamilton, New Zealand  |4 aut 
700 1 |a Gilling  |D Peter  |u Department of Surgery, University of Auckland, Auckland, New Zealand  |4 aut 
773 0 |t International Journal of Clinical Oncology  |d Springer Japan  |g 20/4(2015-08-01), 814-820  |x 1341-9625  |q 20:4<814  |1 2015  |2 20  |o 10147 
856 4 0 |u https://doi.org/10.1007/s10147-014-0781-4  |q text/html  |z Onlinezugriff via DOI 
898 |a BK010053  |b XK010053  |c XK010000 
900 7 |a Metadata rights reserved  |b Springer special CC-BY-NC licence  |2 nationallicence 
908 |D 1  |a research-article  |2 jats 
949 |B NATIONALLICENCE  |F NATIONALLICENCE  |b NL-springer 
950 |B NATIONALLICENCE  |P 856  |E 40  |u https://doi.org/10.1007/s10147-014-0781-4  |q text/html  |z Onlinezugriff via DOI 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Obertová  |D Zuzana  |u Waikato Clinical School, Peter Rothwell Academic Centre, University of Auckland, Private Bag 3200, 3240, Hamilton, New Zealand  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Lawrenson  |D Ross  |u Waikato Clinical School, Peter Rothwell Academic Centre, University of Auckland, Private Bag 3200, 3240, Hamilton, New Zealand  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Scott  |D Nina  |u Te Puna Oranga, Waikato District Health Board, Hamilton, New Zealand  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Holmes  |D Michael  |u Urology Department, Waikato Hospital, Hamilton, New Zealand  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Brown  |D Charis  |u Waikato Clinical School, Peter Rothwell Academic Centre, University of Auckland, Private Bag 3200, 3240, Hamilton, New Zealand  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Lao  |D Chunhuan  |u Waikato Clinical School, Peter Rothwell Academic Centre, University of Auckland, Private Bag 3200, 3240, Hamilton, New Zealand  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Tyrie  |D Leanne  |u Radiation Oncology, Waikato Hospital, Hamilton, New Zealand  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Gilling  |D Peter  |u Department of Surgery, University of Auckland, Auckland, New Zealand  |4 aut 
950 |B NATIONALLICENCE  |P 773  |E 0-  |t International Journal of Clinical Oncology  |d Springer Japan  |g 20/4(2015-08-01), 814-820  |x 1341-9625  |q 20:4<814  |1 2015  |2 20  |o 10147